Showing 5441-5450 of 8846 results for "".
- FDA Approves Sonoma Pharmaceuticals' Antimicrobial Post-Therapy Gelhttps://practicaldermatology.com/news/fda-approves-sonoma-pharmaceuticals-antimicrobial-post-therapy-gel/2457813/Sonoma Pharmaceuticals, Inc. has received a new 510(k) clearance from the FDA for an antimicrobial post-therapy gel. Under the supervision of a healthcare professional, the new product is intended for the management of post-non-ablative laser therapy procedures and post-microdermabrasion therapy
- Aclaris Partners with Cipher to Seek Approval and Commercialize A-101 40% for Seborrheic Keratoses in Canadahttps://practicaldermatology.com/news/aclaris-partners-with-cipher-to-seek-approval-and-commercialize-a-101-40-for-seborrheic-keratoses-in-canada/2457814/Aclaris Therapeutics, Inc., has licensed the Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses (A-101 40%) to Cipher Pharmaceuticals. A-101 40% was FDA approved in December 2017 and is marketed by Aclaris in the U.S. under the tradename E
- BTL to Showcase Groundbreaking Research, Latest Innovation at American Society for Laser Medicine & Surgery Annual Conferencehttps://practicaldermatology.com/news/btl-to-showcase-groundbreaking-research-latest-innovation-at-american-society-for-laser-medicine-surgery-annual-conference/2457817/BTL has had nine scientific abstracts and four ePosters accepted for presentation at the 38th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS) tak
- ASDSA Applauds USPSTF Endorsement of Behavioral Counseling to Prevent Skin Cancerhttps://practicaldermatology.com/news/asdsa-applauds-uspstf-endorsement-of-behavioral-counseling-to-prevent-skin-cancer/2457820/The American Society for Dermatologic Surgery Association (ASDSA) applauds the recent US Preventive Service Task Force (USPSTF) endorsement of behavioral counseling to prevent skin cancer for individuals aged six months to 24 years
- American Academy of Dermatology Elects New Officers, Board Membershttps://practicaldermatology.com/news/american-academy-of-dermatology-elects-new-officers-board-members/2457825/The American Academy of Dermatology named its new officers and board members who will represent the more than 19,000 physicians who specialize in the diagnosis and medical, surgical and cosmetic treatment of skin, hair, and nail conditions. These officers and board members, all of whom are board-
- FDA Approves Label Update for Cimzia Addressing Low Risk of Fetal Exposurehttps://practicaldermatology.com/news/fda-approves-label-update-for-cimzia-addressing-low-risk-of-fetal-exposure/2457828/The FDA has approved a label update that includes pharmacokinetic data showing negligible to low transfer of Cimzia® (certolizumab pegol) through placenta and minimal transfer to breast milk fr
- EpigenCare Named as Johnson & Johnson Innovation Finalist in Skincare Challengehttps://practicaldermatology.com/news/epigencare-named-as-johnson-johnson-innovation-finalist-in-skincare-challenge/2457829/EpigenCare Inc., a personalized skincare startup company, is a finalist in Johnson & Johnson Innovation’s Digital Beauty Quickfire Challenge. The Challenge
- Did New USPSTF Recommendations on Skin Cancer Prevention Counseling Go Far Enough? AADA Reactshttps://practicaldermatology.com/news/did-new-uspstf-recommendations-on-skin-cancer-prevention-counselling-go-far-enough-aada-reacts/2457830/The U.S. Preventive Services Task Force (USPSTF) is calling for behavioral counseling to help reduce the risk of skin cancer from ultraviolet (UV) radiation in people aged 6 months to 24 years with fair skin types. The new USPSTF recommendation statement updates a 2012 recommendation on b
- Sun Pharma: FDA Approves Ilumya for Adult Psoriasishttps://practicaldermatology.com/news/sun-pharma-fda-approves-ilumya-for-adult-psoriasis/2457831/The FDA has approved Ilumya™ (tildrakizumab-asmn) from Sun Pharma for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya selectively binds to the p19 subunit of IL-23 a
- Proscia Inks Agreement to Bring Deep-Learning Technology to Dermatopathologyhttps://practicaldermatology.com/news/proscia-inks-agreement-to-bring-deep-learning-technology-to-dermatopathology/2457832/Proscia Inc., creators of AI-powered digital pathology software, signed a first-of-its-kind agreement with one of the largest dermatopathology labs in the country. This agreement provides Proscia with exclusive access to pathology slides and expert pathologist ground-truth data for an arr